Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc > from the mouth of Paladin CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by teeveeon Feb 18, 2010 12:05am
427 Views
Post# 16794057

RE: from the mouth of Paladin CEO

RE: from the mouth of Paladin CEO“We think there is a lot of upside in the company.”
Yes, Paladin does have a lot of upside. In the event there are any milestone payments, or revenue payments from LUX, Paladin skims 20% off the top before ISA sees a dime. 20% is the cream.  ISA will be lucky to continue to cover overheads.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities